The global Non-alcoholic Steatohepatitis (NASH) market is expected to reach USD 180.09 Billion by 2028, according to a new report by Reports and Data. This can be mainly associated with increasing consumption of fats globally. Based on statistics, Nonalcoholic Fatty Liver Disease (NAFFLD) affects around 80 million to 100 million Americans. NAFLD is expected to become the most common chronic liver condition globally in relation to the obesity and type 2 diabetes in the coming years. Estimates suggest that the incidence of NASH is projected to witness an increase of around 63% between 2015 and 2030.
%20Market.jpg)
Increase in the number of expected launch of pipeline drugs is also a significant factor stimulating market demand. The current statistics for the U.S. suggest that the healthcare cost associated with NASH is around USD 5 billion. Since the incidence of NASH is projected to rise significantly, estimates suggest that, if unchecked, the healthcare costs associated with NASH could rise up to USD 18 billion by 2030. Companies around the world have been focusing on bringing out new drugs in the market for the treatment of the disease.
North America is expected to be a key revenue generating region in the forecast period. The market is projected to grow at a CAGR of 53% in the forecast period. Increasing incidence of disease in the region has created a growth opportunity for the drug makers. Manufacturers have been focusing on bringing out new drugs. For instance: Recently in November 2019, Gilead Sciences, Inc. unveiled that its drug Selonsertib which is a dual anti-apoptotic and anti-inflammatory drug is currently undergoing Phase-3 trials for NASH compensated cirrhosis and NASH fibrosis.
Request a sample Report of the Non-Alcoholic Steatohepatitis (NASH) Market @ https://www.reportsanddata.com/download-free-sample/1111
Further key findings from the report suggest
- Elafibranor is projected to be one of the fastest growing drugs of the NASH market. The segment is projected to grow at a CAGR of 55.4% in the forecast period. The drug which is an oral treatment is GENFIT’s lead pipeline product. It has been positioned as a first-in-class drug to treat NASH. The drug is currently being evaluated in the clinical Phase 3 study RESOLVE-IT.
- North American market is forecasted to grow at a CAGR of 53% in the coming years. The disease is considered to be one of the leading causes of cirrhosis in adults in the U.S. High incidence of diabetes and obesity in the region are considered to be the main reason behind increasing incidence of NASH. Based on American Liver Foundation's National Medical Advisory Committee currently around 30 million Americans have been diagnosed with NASH. Additionally, around 90% of the NASH patients suffer from either obesity or diabetes.
Inquiry Before Buying @ https://www.reportsanddata.com/inquiry-before-buying/1111
Key Players covered in this report are:
Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics. Gilead Sciences
Disease Cause Outlook (Revenue, USD Million; 2018-2028)
- Hypertension
- Heart Disease
- High Blood Lipid
- Type 2 Diabetes
- Obesity
Drug Type Outlook (Revenue, USD Million; 2018-2028)
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cenicriviroc
- Others
End-user Outlook (Revenue, USD Million; 2018-2028)
- Hospitals
- Clinics
- Homecare settings
Based on Region market is segmented into:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Major Points covered in this report are as below:
- The Non-Alcoholic Steatohepatitis (NASH) industry development trends and marketing channels are analyzed. The feasibility of new investment projects are assessed and overall research conclusions offered.
- Non-Alcoholic Steatohepatitis (NASH) industry development trends, marketing channels, feasibility of new investment projects, and overall conclusions of research are presented.
With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
As a valuable source of guidance and direction for companies and individuals interested in the market, the report provides key statistics on the state of the industry through tables and figures. - Development policies and plans, manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost, price, revenue and gross margins.
- This report also analyzes production processes, production costs and import/export figures, as well as cost, price, revenue and gross margins, as well as development policies
- The Non-Alcoholic Steatohepatitis (NASH) Market report provides key statistics on the market status of the Non-Alcoholic Steatohepatitis (NASH) manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
As well as providing key statistics on the market status of the Non-Alcoholic Steatohepatitis (NASH) manufacturers, the Non-Alcoholic Steatohepatitis (NASH) Market report provides valuable guidance and direction for companies and individuals interested in the industry.
We can also provide the customized data for separate regions like North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa
Ask For customization of Report @ https://www.reportsanddata.com/request-customization-form/1111
This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth.
Explore More Industry Research by Reports and Data:
Burkitt Lymphoma Market @ https://www.biospace.com/article/increase-in-cancer-incidence-and-key-players-investing-in-r-and-d-is-expected-to-drive-burkitt-lymphoma-market-growth-till-2030-reports-and-data/
Anxiety Disorder and Depression Treatment Market @ https://www.biospace.com/article/anxiety-disorder-and-depression-treatment-market-is-expected-to-reach-usd-19-53-billion-by-2028-/
Non-Alcoholic Steatohepatitis (NASH) Market @ https://www.biospace.com/article/non-alcoholic-steatohepatitis-nash-market-will-reach-usd-180-09-billion-by-2028-/
Cerebrospinal Fluid (CSF) Management Market @ https://www.biospace.com/article/cerebrospinal-fluid-csf-management-market-is-expected-to-reach-usd-2-31-billion-in-2028-/
Immunomodulators Market @ https://www.biospace.com/article/immunomodulators-market-growth-prospects-latest-trend-analysis-development-and-forecast-2027/
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
0 Comments
Post a Comment